External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology Pathology Visions 2024
Roche and Genentech at

Pathology Visions 2024

November 03 - November 05
Orlando, Florida
pathologyvisions.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Nov 8 / Roche
Mutation Detection in Lung Cancer Using Heterogeneity Derived from Quantitative Pathology Features
In this study, we test the hypothesis that morphological heterogeneity in tumor cell populations reflects the level of genetic variation, which in turn provides information about the presence of mutations. This study aims to harness tumor heterogeneity derived from Quantitative Pathology Features (QPFs) for the classification of known (mutation or fusion) and unknown drivers in lung cancer patients.
Oncology Lung Cancer Pathology-Visions-2024
12:00 PM
Duration 1hr Orlando, Florida
Mutation Detection in Lung Cancer Using Heterogeneity Derived from Quantitative Pathology Features
Yao Nie
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.